🚀 Want to Shape the Future of Drug Discovery? We’re on a mission to revolutionize therapeutics with cyclic peptides + AI, and we’re looking for a Senior Cloud & DevOps Engineer to take our cloud infrastructure to the next level. 🔬 You’ll love this role if you: ✔️ Thrive in high-growth, mission-driven startups ✔️ Get excited about building scalable, secure, and cost-efficient cloud systems ✔️ Want to power real-world drug discovery with cutting-edge infrastructure If you’re ready to design, automate, and scale the backbone of AI-driven drug discovery, we’d love to connect! #hiring #cloud #devops #GCP #infrastructure #biotech #drugdiscovery https://lnkd.in/dANHHFu3
Menten AI
Biotechnology Research
San Francisco, CA 5,232 followers
Unlocking the potential of peptides macrocycles to create tomorrow's life-changing medicines with Generative AI.
About us
Menten AI is pioneering generative AI to design cyclic peptide therapeutics for drug targets beyond the reach of small molecules and biologics. Our proprietary platform, MAUD 1.0, enables the rapid creation of macrocycles with drug-like properties such as oral bioavailability and cell permeability. We partner with top-10 pharma leaders (e.g., Bristol Myers Squibb) to accelerate preclinical discovery, and we are backed by world-class investors including Social Impact Capital, Uncork Capital, Khosla Ventures, and Y Combinator.
- Website
-
http://menten.ai
External link for Menten AI
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- San Francisco, CA
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
Get directions
San Francisco, CA 94111, US
-
Get directions
100 College St
Toronto, Ontario, CA
Employees at Menten AI
-
Chinmaya Rath
Biotech Builder: Venture Partner, Executive, Board Member, Strategic Advisor
-
Helen H. Liang, PhD
Founder & Managing Partner of FoundersX Ventures. Board Director. Featured on WSJ and Business Insider. Invited Speaker at TechCrunch. Nvidia VC…
-
Hans Melo
Co-Founder and CEO at Menten AI - We’re hiring!
-
Elliott Dolan, PhD
PhD in Chemistry and Chemical Biology and Quantitative Biomedicine
Updates
-
🚀 Want to Shape the Future of Drug Discovery? We’re Hiring: Senior Cloud & DevOps Engineer (Remote) 🌍 We’re on a mission to revolutionize therapeutics with cyclic peptides + AI, and we’re looking for a Senior Cloud & DevOps Engineer to take our cloud infrastructure to the next level. 🔬 You’ll love this role if you: ✔️ Thrive in high-growth, mission-driven startups ✔️ Get excited about building scalable, secure, and cost-efficient cloud systems ✔️ Want to power real-world drug discovery with cutting-edge infrastructure If you’re ready to design, automate, and scale the backbone of AI-driven drug discovery, we’d love to connect! #hiring #cloud #devops #GCP #infrastructure #biotech #drugdiscovery https://lnkd.in/d9q2iger
-
We’re excited to share a recent preprint led by our cofounder, Vikram K. Mulligan - now available for reading: 🔗 https://lnkd.in/e77kke4H We’re proud to see our scientific contributions pushing the field forward. Stay tuned—more to come. 👏
-
We are proud to partner with Google by using generative AI to transform drug discovery 🤝. By leveraging Google Cloud’s high-performance computing and advanced ML capabilities, we, at Menten AI, accelerate the design and optimization of peptide therapeutics to unlock new possibilities in medicine 🚀. https://lnkd.in/eztBuig2
-
Interested in the future of peptide-based therapeutics? 🤔 We’re proud to share that our CEO, Hans Melo, will be speaking at the Peptide Therapeutics Forum in Basel, Switzerland on June 5–6: https://ptf25.scg.ch/ He will be sharing how Menten AI's innovations in cyclic peptide drug design are shaping the future of peptide-based therapeutics. 🚀
-
-
Excited to be at Bio-Europe Spring in Milan this week! Make sure to join my session on Wednesday to learn about the latest developments in generative AI for peptide therapeutics. #bioeuropespring #aidrugdiscovery
-
-
Don’t miss the chance to meet Hans Melo at NextGen BioMed in London over the next three days as he discusses Menten AI's generative AI platform! 👋
We are excited to share that our CEO, Hans Melo, will be presenting at NextGen BioMed in London UK 🎉. He will be discussing Menten AI's generative AI platform for multi-parameter design of cyclic peptide drugs for challenging drug targets beyond the reach of small molecules and biologics 💊.
-
-
Menten AI reposted this
Join us at BIO-Europe Spring as Hans Melo, CEO of Menten AI, takes the stage to showcase their latest innovations in Drug Discovery and Development. Don’t miss this opportunity to hear firsthand how they are shaping the future of biotech! 🤝 Register now and start engaging: https://lnkd.in/e5nE43yr 📅 BIO-Europe Spring | March 17–19, 2025 📍 Milan, Italy